Europe Benign Prostatic Hyperplasic Devices Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Resectoscopes, Urology Laser, Radiofrequency Ablation Devices, Prostatic Stents, and Implants), Procedure Type (Transurethral Microwave Therapy, Transurethral Resection of the Prostate, Transurethral Needle Ablation of the Prostate, Laser Surgery, Urolift Surgery, and Others), and End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others)
The benign prostatic hyperplasic devices market in Europe is expected to grow from US$ 648.39 million in 2022 to US$ 994.84 million by 2028; it is estimated to grow at a CAGR of 7.4% from 2022 to 2028.
Players operating in the benign prostatic hyperplasic devices industry focus on investing high amounts in the development of advanced surgical technologies as alternatives to conventional techniques. Advanced devices enabled with new technologies help provide immediate relief and reduce morbidity. In January 2022, ProVerum, an Irish start-up supported by EIT Health, received US$ 31.22 million in Series A funding from Gilde Healthcare, Lightstone Ventures, and Atlantic Bridge. ProVerum has developed ProVee, a cutting-edge treatment solution for men with symptomatic BPH, and it aims to market its innovative device in Europe with the help of recent funding. Further, in June 2021, Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by BPH or enlarged prostate, declared the completion of its Series B funding round with a total of US$ 24 million. The investment was led by Invus Opportunities and included participation from Medical Technology Venture Partners, F-Prime Capital, CloudStone Capital, Astia Angels, Golden Seeds, SV Tech Ventures, etc. In June 2021, Procept Biorobotics raised US$ 85 million to commercialize the AquaBeam system as a global BPH treatment. With this product, the company intends to make an impact with its water-based robotic technology in the field of prostate surgery. The series G financing was led by Fidelity Management & Research Company, with additional backing from T. Rowe Price Associates, CPMG, Perceptive Advisors, Viking Global Investors, and Duquesne Family Office. The rise in such investments, funds, and grants for research in the field of BPH treatments is bolstering the benign prostatic hyperplasic devices market growth.
Europe Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028 (US$ Million)
Europe Benign Prostatic Hyperplasic Devices Market Segmentation
The Europe benign prostatic hyperplasic devices market is segmented on the basis of product, procedure type, end user, and country. Based on product, the market is segmented into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. The resectoscopes segment is expected to hold the largest share of the market in 2022. On the other hand, the urology lasers segment is expected to register the highest CAGR during the forecast period. Based on procedure type, the Europe benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. The transurethral resection of the prostate segment held the largest market share in 2022, and it is also expected to register the highest CAGR in the market during the forecast period. Based on end user, the Europe benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospital segment held the largest market share in 2022, while the clinics segment is expected to register the highest CAGR during the forecast period. Based on country, the Europe benign prostatic hyperplasic devices market is segmented into U.K., Germany, France, Italy, Spain, and Rest of Europe. In 2022, Germany held a larger market share. On the other side, and it is also expected to register a higher CAGR during the forecast period.
KARL STORZ SE & Co. KG; Olympus Corporation; Boston Scientific Corporation; Teleflex Incorporated; and Richard Wolf GmbH are among the leading companies in the Europe benign prostatic hyperplasic devices market.
Reasons to buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe benign prostatic hyperplasic devices market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe benign prostatic hyperplasic devices market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the benign prostatic hyperplasic devices market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook